NASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis $4.08 +0.29 (+7.65%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$4.45 +0.37 (+9.07%) As of 03/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About bluebird bio Stock (NASDAQ:BLUE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get bluebird bio alerts:Sign Up Key Stats Today's Range$3.71▼$4.4350-Day Range$3.73▼$8.3552-Week Range$3.56▼$28.60Volume2.08 million shsAverage Volume363,888 shsMarket Capitalization$39.67 millionP/E RatioN/ADividend YieldN/APrice Target$51.00Consensus RatingHold Company Overviewbluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Read More… Remove Ads bluebird bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreBLUE MarketRank™: bluebird bio scored higher than 59% of companies evaluated by MarketBeat, and ranked 431st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst Coveragebluebird bio has only been the subject of 4 research reports in the past 90 days.Read more about bluebird bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($27.25) to ($11.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about bluebird bio's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted19.19% of the float of bluebird bio has been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in bluebird bio has recently decreased by 7.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.19% of the float of bluebird bio has been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in bluebird bio has recently decreased by 7.04%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment0.25 News Sentimentbluebird bio has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for bluebird bio this week, compared to 5 articles on an average week.Search Interest11 people have searched for BLUE on MarketBeat in the last 30 days. This is an increase of 175% compared to the previous 30 days.MarketBeat Follows9 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,831.00 in company stock.Percentage Held by InsidersOnly 1.40% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about bluebird bio's insider trading history. Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Stock News HeadlinesBluebird Bio confirms receipt non-binding proposal from AyrmidMarch 29 at 2:17 AM | markets.businessinsider.comBluebird bio reports another acquisition offer for $45M upfrontMarch 28 at 9:17 PM | bizjournals.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. March 30, 2025 | Porter & Company (Ad)Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- UpdateMarch 28 at 6:00 PM | marketwatch.comBluebird bio receives non-binding bid for up to $110.5 millionMarch 28 at 6:00 PM | reuters.combluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from AyrmidMarch 28 at 5:04 PM | businesswire.combluebird bio (NASDAQ:BLUE) Stock Crosses Below 200-Day Moving Average - Here's WhyMarch 28 at 3:35 AM | americanbankingnews.combluebird bio (BLUE) Expected to Announce Earnings on MondayMarch 22, 2025 | americanbankingnews.comSee More Headlines BLUE Stock Analysis - Frequently Asked Questions How have BLUE shares performed this year? bluebird bio's stock was trading at $8.34 on January 1st, 2025. Since then, BLUE stock has decreased by 51.1% and is now trading at $4.08. View the best growth stocks for 2025 here. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($13.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($13.80) by $0.60. The company's quarterly revenue was up 17364.8% on a year-over-year basis. When did bluebird bio's stock split? Shares of bluebird bio reverse split on Friday, December 13th 2024. The 1-20 reverse split was announced on Wednesday, December 4th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are bluebird bio's major shareholders? Top institutional investors of bluebird bio include Geode Capital Management LLC (2.40%), Group One Trading LLC, Northern Trust Corp (0.84%) and Lion Point Capital LP (0.81%). Insiders that own company stock include Andrew Obenshain, Nick Leschly, Jason Cole, Thomas J Klima, Richard A Colvin, Christopher Krawtschuk and Anne-Virginie Eggimann. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that bluebird bio investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings11/07/2023Today3/30/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BLUE CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees520Year FoundedN/APrice Target and Rating Average Stock Price Target$51.00 High Stock Price Target$120.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,150.0%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($45.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-211,910,000.00 Net Margins-565.74% Pretax Margin-551.41% Return on Equity-322.46% Return on Assets-53.17% Debt Debt-to-Equity Ratio0.37 Current Ratio0.51 Quick Ratio0.33 Sales & Book Value Annual Sales$53.12 million Price / Sales0.75 Cash FlowN/A Price / Cash FlowN/A Book Value$35.59 per share Price / Book0.11Miscellaneous Outstanding Shares9,722,000Free Float9,586,000Market Cap$39.67 million OptionableOptionable Beta0.76 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:BLUE) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.